Keyphrases
Ovarian Cancer
100%
Utility Assessment
100%
Amifostine
100%
First-line Therapy
100%
Cost-utility
100%
Cyclophosphamide
28%
Cost-effectiveness
28%
Supportive Care
28%
Direct Medical Costs
28%
United States
14%
Chemotherapy
14%
Cisplatin
14%
Neurotoxicity
14%
Nephrotoxicity
14%
Disease Progression
14%
Sensitivity Analysis
14%
Health Status
14%
Lifesaving
14%
Quality-adjusted Life Years
14%
Time to Progression
14%
Female Patients
14%
Cis-platinum
14%
Hematotoxicity
14%
Treatment Toxicity
14%
Cytoprotective Agents
14%
Cancer Therapeutics
14%
Economic Considerations
14%
Disease Threat
14%
Therapeutic Care
14%
Status Change
14%
Cumulative Toxicity
14%
Medicine and Dentistry
Ovarian Cancer
100%
Health Care Cost
100%
Amifostine
100%
Utility Assessment
100%
Cisplatin
28%
Cyclophosphamide
28%
Cost-Effectiveness Analysis
28%
Supportive Care
28%
Malignant Neoplasm
14%
Disease
14%
Nephrotoxicity
14%
Neurotoxicity
14%
Chemotherapy
14%
Health Status
14%
Quality Adjusted Life Year
14%
Cytoprotective Agent
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Cancer
100%
Amifostine
100%
Cisplatin
28%
Cyclophosphamide
28%
Malignant Neoplasm
14%
Disease
14%
Nephrotoxicity
14%
Neurotoxicity
14%
Chemotherapy
14%
Health Status
14%
Cytoprotective Agent
14%
Nursing and Health Professions